Sumitomo Pharma America enters into a CRADA with the NCI to Advance Clinical Understanding of Enzomenib April 22, 2025
Epsilogen Announces Acquisition of TigaTx, Inc. to Create Pan-Isotype Cancer Antibody Company April 16, 2025
Solu Therapeutics Closes $41M Series A Financing; First Patient Dosed in Ph 1 Trial of STX-0712 in Patients with CMML and Other Heme Malignancies April 16, 2025
Scancell Holdings announces partnership with the NHS CVLP to fast-track access for NHS patients into 4th cohort of Ph 2 SCOPE study April 15, 2025
OS Therapies Completes Acquisition of Advaxis Immunotherapies Clinical, Pre-clinical and IP Assets from Ayala Pharmaceuticals April 15, 2025
Oncolytics Biotech Funds Pelareorep’s Development with a Share Purchase Agreement in Partnership with Alumni Capital April 15, 2025
Edity Therapeutics and Aurigene Oncology to Advance a Novel Cell Therapy Program for Solid Tumors April 8, 2025
Boehringer Ingelheim strengthens ADC portfolio with new NBE Therapeutics R&D center in Basel April 8, 2025
BORUZU, First Ready-to-Use Bortezomib Injection for Multiple Myeloma and Mantle Cell Lymphoma, launched April 8, 2025
Relmada Therapeutics Licenses Ph 2 Bladder Cancer Candidate, NDV-01, from Trigone Pharma April 2, 2025
Servier and Black Diamond Therapeutics Announce Global Licensing Agreement for BDTX-4933 March 26, 2025
Harbour BioMed Enters into Global Strategic Collaboration with AstraZeneca to Discover and Develop Next-Gen Therapeutic Antibodies March 26, 2025
Oxford BioTherapeutics Enters into a Strategic Collaboration with Roche to Discover Novel Targets for Antibody-Based Therapeutics for the Treatment of Cancer March 26, 2025
AstraZeneca enters license agreement with Alteogen for subcutaneous formulations of multiple oncology assets March 18, 2025
iOncologi, Inc. Acquires TargImmune Therapeutics to Expand and Strengthen Immunotherapy Pipeline Against Solid Tumors March 18, 2025
Johnson & Johnson to not exercise its option to receive a worldwide license to develop, manufacture and commercialize HexaBody-CD38 March 18, 2025
Aprea Therapeutics Announces Agreement with MD Anderson Cancer Center to Explore APR-1051 as a Potential Treatment for HNSCC March 18, 2025
BioCity Biopharmaceutics Announces Clinical Collaboration to Evaluate BC3195 + KEYTRUDA combination in Patients with Locally Advanced or Metastatic Solid Tumors March 18, 2025
SOTIO Expands ADC Pipeline and Synaffix Collaboration to Develop Two Novel Bispecific Candidates, SOT112 and SOT113 March 18, 2025
ImmunoPrecise Antibodies and a Global Biotechnology Company Enter into a USD $8M-$10M Partnership for the Development of Novel Cancer Therapeutics March 18, 2025
